Pipeline Reality
Separate buyer-verified opportunities from hopeful pipeline and internal optimism.
Anthony W. Luttenberger | Life Sciences Commercial GTM
Make GTM execution measurable.
Advisory for life sciences leaders who need strategy, pipeline, forecast, evidence, and operating reality to align before the number is missed.
- Commercial lens
- Pipeline reality
- Operating lens
- Forecast discipline
- Market lens
- Life sciences complexity
The commercial problem
Most commercial misses start before the number is missed.
Revenue gaps usually appear first as weak stage evidence, optimistic pipeline, unclear ownership, slow decisions, and late discovery of access, reimbursement, regulatory, or evidence friction.
The work is to expose those constraints early enough for leadership to act with precision.
Interactive Diagnostic
Assess pipeline quality, forecast trust, and execution readiness in one focused flow.
Operating Review
Make the commercial system visible enough to manage.
Pipeline, forecast, stage evidence, and life sciences execution risk should be reviewed together, with the same leadership cadence and the same definition of what is real.
Review the operating frameworkAdvisory Areas
Execution questions that should be visible before a board meeting.
Forecast Reliability
Connect forecast categories to proof events, not late-quarter confidence calls.
Operating Alignment
Align people, structure, incentives, metrics, and decision rights around revenue growth.
Commercial Due Diligence
Evaluate GTM readiness, revenue quality, scale risk, and enterprise value implications.
Life Sciences Scale
Surface patient access, evidence, regulatory, clinical, reimbursement, and adoption risk.
Execution Cadence
Turn commercial reviews into decisions, ownership, and measurable next actions.
Life sciences
Pharmaceutical services
Healthcare data
RWD and RWE
Patient access
Commercialization
Executive next step